Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients

Blood

Volumn 127, Issue 3, 2016, Pages 333-342

  Cabagnols, Xenia ^a   Favale, Fabrizia ^a   Pasquier, Florence ^a   Messaoudi, Kahia ^a   Defour, Jean Philippe ^b,c   Ianotto, Jean Christophe ^d   Marzac, Christophe ^e   Le Couedic, Jean Pierre ^a   Droin, Nathalie ^a   Chachoua, Ilyas ^b,c   Favier, Remi ^a   Diop, M'boyba Khadija ^a   Ugo, Valerie ^d   Casadevall, Nicole ^a,e   Debili, Najet ^a   Raslova, Hana ^a   Bellanńe Chantelot, Christine ^a,f   Constantinescu, Stefan N ^b,c   Bluteau, Olivier ^a   Plo, Isabelle ^a   Vainchenker, William ^a,g   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b DE DUVE INSTITUTE   (Belgium)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d BREST UNIVERSITY HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2; MPL RECEPTOR; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; CODON; CYTOKINE; MPL PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; GAIN OF FUNCTION MUTATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENOTYPING TECHNIQUE; HEMATOPOIESIS; HUMAN; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE NEOPLASM; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; THROMBOCYTHEMIA; TRIPLE NEGATIVE ESSENTIAL THROMBOCYTHEMIA; AMINO ACID SUBSTITUTION; CELL LINE; CELL PROLIFERATION; CODON; COHORT ANALYSIS; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; EXOME; GENETICS; GENOTYPE; GRANULOCYTE; HIGH THROUGHPUT SEQUENCING; METABOLISM; MUTATION; PROTEIN TRANSPORT;

AMINO ACID SUBSTITUTION; CELL LINE; CELL PROLIFERATION; CODON; COHORT STUDIES; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOKINES; DNA MUTATIONAL ANALYSIS; EXOME; GENOTYPE; GRANULOCYTES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JANUS KINASE 2; MUTATION; PROTEIN TRANSPORT; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84958162239     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-661983     Document Type: Article

References (49)

1. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28(7):1407-1413.
2. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol. 2010; 91(2):174-179.
3. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol. 2008; 19(4):385-393.
4. Defour JP, Itaya M, Gryshkova V, et al. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc Natl Acad Sci USA. 2013;110(7):2540-2545.
5. Ding J, Komatsu H, Iida S, et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009;114(15):3325-3328.
6. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-4200.
7. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood. 2008;112(1):141-149.
8. Chaligńe R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22(8):1557-1566.
9. He X, Chen Z, Jiang Y, Qiu X, Zhao X. Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases. J Hematol Oncol. 2013;6:11.
10. Kawamata N, Ogawa S, Yamamoto G, et al. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol. 2008;36(11): 1471-1479.
11. Lambert MP, Jiang J, Batra V, Wu C, Tong W. A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia. Am J Hematol. 2012;87(5): 532-534.
12. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol. 2007;35(11):1641-1646.
13. Koren-Michowitz M, Gery S, Tabayashi T, et al. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. Br J Haematol. 2013;161(6):811-820.
14. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010; 116(6):988-992.
15. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
16. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.
17. Wang WA, Groenendyk J, Michalak M. Calreticulin signaling in health and disease. Int J Biochem Cell Biol. 2012;44(6):842-846.
18. Tefferi A, Guglielmelli P, Larson DR, et al. Long-Term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507-2513.
19. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477.
20. Cervantes F, Barosi G. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging. Semin Oncol. 2005;32(4):395-402.
21. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol. 1999;104(4):730-737.
22. James C, Ugo V, Le Coúedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
23. Chaligńe R, James C, Tonetti C, et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood. 2007; 110(10):3735-3743.
24. Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia. 2015;29(1):249-252.
25. Saliba J, Saint-Martin C, Di Stefano A, et al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat Genet. 2015;47(10):1131-1140.
26. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4(9): 1088-1101.
27. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood. 2008;112(4):1402-1412.
28. Kohlhuber F, Rogers NC, Watling D, et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol. 1997; 17(2):695-706.
29. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem. 2002;277(49): 47954-47963.
30. Sliva D, Wood TJ, Schindler C, Lobie PE, Norstedt G. Growth hormone specifically regulates serine protease inhibitor gene transcription via gamma-Activated sequence-like DNA elements. J Biol Chem. 1994;269(42): 26208-26214.
31. Marty C, Saint-Martin C, Pecquet C, et al. Germline JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014;123(9):1372-1383.
32. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12): 1472-1478.
33. McKerrell T, Park N, Moreno T, et al; Understanding Society Scientific Group. Leukemia-Associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Reports. 2015;10(8): 1239-1245.
34. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
35. Jaiswal S, Fontanillas P, Flannick J, et al. Agerelated clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26): 2488-2498.
36. Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell. 2014;25(3): 379-392.
37. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 2006;108(12):3913-3915.
38. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2015; 127(3):325-332.
39. Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronicphase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 2010;24(10):1713-1718.
40. Velazquez L, Cheng AM, Fleming HE, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med. 2002;195(12):1599-1611.
41. Vilaine M, Gourain V, Cleyrat C, et al. Germline MPLW515R mutation in a family with isolated thrombocytosis [abstract]. Blood. 2012;120(21). Abstract 1764.
42. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci USA. 2004;101(31): 11444-11447.
43. Lannutti BJ, Epp A, Roy J, Chen J, Josephson NC. Incomplete restoration of Mpl expression in the mpl-/-mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood. 2009;113(8):1778-1785.
44. Meyer SC, Keller MD, Woods BA, et al. Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood. 2014; 124(14):2280-2284.
45. Ng AP, Kauppi M, Metcalf D, et al. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci USA. 2014; 111(16):5884-5889.
46. Pecquet C, Staerk J, Chaligńe R, et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood. 2010;115(5):1037-1048.
47. Drachman JG, Kaushansky K. Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci USA. 1997;94(6):2350-2355.
48. Sangkhae V, Saur SJ, Kaushansky A, Kaushansky K, Hitchcock IS. Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietininduced signaling. Exp Hematol. 2014;42(6): 477-486.
49. Karow A, Nienhold R, Lundberg P, et al. Mutational profile of childhood myeloproliferative neoplasms [published online ahead of print July 30, 2015]. Leukemia. doi:10.1038/leu.2015.205.